Provided by Tiger Fintech (Singapore) Pte. Ltd.

Adicet Bio, Inc.

0.5258
-0.0455-7.96%
Post-market: 0.54000.0142+2.70%19:21 EDT
Volume:361.32K
Turnover:201.49K
Market Cap:43.48M
PE:-0.39
High:0.6099
Open:0.5800
Low:0.5229
Close:0.5713
Loading ...

BRIEF-Adicet Bio Appoints Michael Grissinger To The Board Of Directors

Reuters
·
17 Apr

Adicet Bio Appoints Michael Grissinger to the Board of Directors

THOMSON REUTERS
·
17 Apr

BRIEF-Adicet Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
01 Apr

Adicet Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
01 Apr

Adicet Bio to Participate in 2025 Canaccord Genuity Horizons in Oncology Virtual Conference

Business Wire
·
31 Mar

Adicet Bio (ACET): Among the Penny Stocks With Huge Upside Potential According to Analysts

Insider Monkey
·
23 Mar

Adicet Bio Price Target Maintained With a $7.00/Share by Guggenheim

Dow Jones
·
21 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
07 Mar

BRIEF-Adicet Bio Inc Files For Mixed Shelf Of Up To $250 Million

Reuters
·
07 Mar

BRIEF-Adicet Bio Q4 Basic EPS USD -0.32

Reuters
·
07 Mar

Adicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company Progress

Business Wire
·
07 Mar

Adicet Announces Poster Presentations Highlighting Adi-270 Data at the Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting

THOMSON REUTERS
·
03 Mar

Adicet Announces Poster Presentations Highlighting ADI-270 Data at the Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting

Business Wire
·
03 Mar

Adicet Bio shares rise on FDA Fast Track Designation for ADI-001

Investing.com
·
27 Feb

Adicet Bio Receives FDA Fast Track Designation for Adi-001 for the Treatment of Systemic Sclerosis (Ssc)

THOMSON REUTERS
·
27 Feb

Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Systemic Sclerosis (SSc)

Business Wire
·
27 Feb

H.C. Wainwright Sticks to Its Hold Rating for Adicet Bio (ACET)

TIPRANKS
·
05 Feb

Adicet Bio Receives FDA Fast Track Designation for Adi-001 for the Treatment of Refractory Systemic Lupus Erythematosus (Sle) With Extrarenal Involvement

THOMSON REUTERS
·
05 Feb

Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE) with Extrarenal Involvement

Business Wire
·
05 Feb

Adicet Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
01 Feb